Kompass Autoimmun最新文献_第9页

Spektrum Autoimmun – wissenswert, kompakt, anregend

Kompass Autoimmun Pub Date : 2022-02-01 DOI: 10.1159/000522104

引用次数: 0

AutoimmunCampus

Kompass Autoimmun Pub Date : 2022-02-01 DOI: 10.1159/000522181

引用次数: 0

Front & Back Matter 正面和背面

Kompass Autoimmun Pub Date : 2022-02-01 DOI: 10.1159/000523694

Wissenschaftlicher Beirat

引用次数: 0

Immunbedingte unerwünschte Ereignisse unter Therapie mit Immun-Checkpoint-Inhibitoren 免疫障碍药物使用免疫检测仪

Kompass Autoimmun Pub Date : 2022-02-01 DOI: 10.1159/000522467

J. Leipe, K. Benesova

引用次数: 0

7 Fragen an die Trägerin des Friedmund Neumann Preises 2021 "弗里德曼•诺依曼代孕代理7个问题

Kompass Autoimmun Pub Date : 2022-02-01 DOI: 10.1159/000522182

引用次数: 0

Erste EULAR-Empfehlungen (Points to Consider) für rheumatische Nebenwirkungen von Checkpoint-Inhibitoren 第一个关于智商抑制剂的不客气建议

Kompass Autoimmun Pub Date : 2022-01-28 DOI: 10.1159/000521755

M. Aringer

{"title":"Erste EULAR-Empfehlungen (Points to Consider) für rheumatische Nebenwirkungen von Checkpoint-Inhibitoren","authors":"M. Aringer","doi":"10.1159/000521755","DOIUrl":"https://doi.org/10.1159/000521755","url":null,"abstract":"Background: Rheumatic and musculoskeletal immune-related adverse events (irAEs) are observed in about 10% of patients with cancer receiving checkpoint inhibitors (CPIs). Given the recent emergence of these events and the lack of guidance for rheumatologists addressing them, a European League Against Rheumatism task force was convened to harmonise expert opinion regarding their identification and management. Methods: First, the group formulated research questions for a systematic literature review. Then, based on literature and using a consensus procedure, 4 overarching principles and 10 points to consider were developed. Results: The overarching principles defined the role of rheumatologists in the management of irAEs, highlighting the shared decision-making process between patients, oncologists and rheumatologists. The points to consider inform rheumatologists on the wide spectrum of musculoskeletal irAEs, not fulfilling usual classification criteria of rheumatic diseases, and their differential diagnoses. Early referral and facilitated access to rheumatologist are recommended, to document the target organ inflammation. Regarding therapeutic, three treatment escalations were defined: (1) local/systemic glucocorticoids if symptoms are not controlled by symptomatic treatment, then tapered to the lowest efficient dose, (2) conventional synthetic disease-modifying antirheumatic drugs, in case of inadequate response to glucocorticoids or for steroid sparing and (3) biological disease-modifying antirheumatic drugs, for severe or refractory irAEs. A warning has been made on severe myositis, a life-threatening situation, requiring high dose of glucocorticoids and close monitoring. For patients with pre-existing rheumatic disease, baseline immunosuppressive regimen should be kept at the lowest efficient dose before starting immunotherapies. Conclusion: These statements provide guidance on diagnosis and management of rheumatic irAEs and aim to support future international collaborations.","PeriodicalId":17887,"journal":{"name":"Kompass Autoimmun","volume":"93 1","pages":"12 - 13"},"PeriodicalIF":0.0,"publicationDate":"2022-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78256260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Gewebsresidente CD8+ T-Zellen als therapeutisches Ziel bei der Checkpunkttherapie-assoziierten Immunenterokolitis CD8+ t细胞作为治疗感染病毒的治疗目标

Kompass Autoimmun Pub Date : 2022-01-28 DOI: 10.1159/000522047

B. Bengsch

{"title":"Gewebsresidente CD8+ T-Zellen als therapeutisches Ziel bei der Checkpunkttherapie-assoziierten Immunenterokolitis","authors":"B. Bengsch","doi":"10.1159/000522047","DOIUrl":"https://doi.org/10.1159/000522047","url":null,"abstract":"Background & Aims: The pathogenesis of immune checkpoint inhibitor (ICI)-colitis remains incompletely understood. We sought to identify key cellular drivers of ICI-colitis and their similarities to idiopathic ulcerative colitis, and to determine potential novel therapeutic targets. Methods: We used a cross-sectional approach to study patients with ICI-colitis, those receiving ICI without the development of colitis, idiopathic ulcerative colitis, and healthy controls. A subset of patients with ICI-colitis were studied longitudinally. We applied a range of methods, including multiparameter and spectral flow cytometry, spectral immunofluorescence microscopy, targeted gene panels, and bulk and single-cell RNA sequencing. Results: We demonstrate CD8+ tissue resident memory T (TRM) cells are the dominant activated T cell subset in ICI-colitis. The pattern of gastrointestinal immunopathology is distinct from ulcerative colitis at both the immune and epithelial-signaling levels. CD8+ TRM cell activation correlates with clinical and endoscopic ICI-colitis severity. Single-cell RNA sequencing analysis confirms activated CD8+ TRM cells express high levels of transcripts for checkpoint inhibitors and interferon-gamma in ICI-colitis. We demonstrate similar findings in both anti-CTLA-4/PD-1 combination therapy and in anti-PD-1 inhibitor-associated colitis. On the basis of our data, we successfully targeted this pathway in a patient with refractory ICI-colitis, using the JAK inhibitor tofacitinib. Conclusions: Interferon gamma-producing CD8+ TRM cells are a pathological hallmark of ICI-colitis and a novel target for therapy.","PeriodicalId":17887,"journal":{"name":"Kompass Autoimmun","volume":"35 1","pages":"17 - 19"},"PeriodicalIF":0.0,"publicationDate":"2022-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88596644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nebenwirkungsprofil von Prednisolon und Methotrexat bei Patienten mit Sarkoidose 含石棺的病人的副作用描述

Kompass Autoimmun Pub Date : 2022-01-28 DOI: 10.1159/000521520

N. Kahn

引用次数: 0

Erhöhen Glukokortikoide auch kurzfristig das kardiovaskuläre Risiko? Eine Studie in Glukokortikoid-naiven Patienten mit rheumatoider Arthritis 短期内葡萄糖也会增加心脏衰竭的风险吗?一项在胆囊性关节炎患者身上的研究

Kompass Autoimmun Pub Date : 2022-01-28 DOI: 10.1159/000521756

Carina Mihai

{"title":"Erhöhen Glukokortikoide auch kurzfristig das kardiovaskuläre Risiko? Eine Studie in Glukokortikoid-naiven Patienten mit rheumatoider Arthritis","authors":"Carina Mihai","doi":"10.1159/000521756","DOIUrl":"https://doi.org/10.1159/000521756","url":null,"abstract":"Objectives: Rheumatoid arthritis (RA), along with glucocorticoid use, is associated with cardiovascular disease. Cardiovascular safety of glucocorticoids in RA is controversial and may be related to dose and duration of use. We determined if initiating glucocorticoids in steroid-naive RA patients would increase cardiovascular event (CVE) risk in a dose and duration-dependent manner over short-term intervals. Methods: Patients enrolled in CorEvitas (formerly Corrona) RA registry. Cox proportional-hazards models estimated adjusted HRs (aHR) for incident CVE in patients who initiated glucocorticoid treatment, adjusting for RA duration, traditional cardiovascular risk factors and time-varying covariates: Clinical Disease activity Index, disease-modifying antirheumatic drugs use and prednisone-equivalent use. Glucocorticoid use assessed current daily dose, cumulative dose and duration of use over rolling intervals of preceding 6 months and 1 year. Results: 19 902 patients met criteria. 1106 CVE occurred (1.66/100 person-years). Increased aHR occurred at current doses of ≥5–9 mg 1.56 (1.18–2.06) and ≥10 mg 1.91 (1.31–2.79), without increased risk at 0–4 mg 1.04 (0.55–1.59). Cumulative dose over preceding 6 months showed increased aHR at 751–1100 mg 1.43 (1.04–1.98) and >1100 mg 2.05 (1.42–2.94), without increased risk at lower doses; duration of use over preceding 6 months exhibited increased aHR for >81 days of use 1.54 (1.08–2.32), without increased risk at shorter durations. One-year analyses were consistent. Conclusions:Over preceding 6-month and 1-year intervals, initiating glucocorticoids in steroid-naïve RA patients is associated with increased risk of CVE at daily doses ≥5 mg and increased cumulative dose and duration of use. No association with risk for CVE was found with daily prednisone of ≤4 mg or shorter cumulative doses and durations.","PeriodicalId":17887,"journal":{"name":"Kompass Autoimmun","volume":"26 1","pages":"22 - 24"},"PeriodicalIF":0.0,"publicationDate":"2022-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86652358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

PharmaNews

Kompass Autoimmun Pub Date : 2021-11-01 DOI: 10.1159/000520209

{"title":"PharmaNews","authors":"","doi":"10.1159/000520209","DOIUrl":"https://doi.org/10.1159/000520209","url":null,"abstract":"Auch 3 Jahre nach der Zulassung von Benralizumab (Fasenra®) bei schwerem eosinophilem Asthma [1] gibt es aktuelle, aufschlussreiche Studiendaten zum monoklonalen Antikörper, die neue Erkenntnisse für die medizinische Praxis mit sich bringen: So belegen Ergebnisse der offenen Phase-III-Extensionsstudie MELTEMI ein konsistentes Sicherheitsprofil, das durchgängig über bis zu 5 Jahre mit den bekannten Sicherheitsdaten übereinstimmt [2]. Die größte bisher durchgeführte Studie zur Reduktion von oralen Kortikosteroiden (OCS) bei schwerem eosinophilem Asthma, PONENTE, zeigt ferner, dass mit Benralizumab und einem personalisierten Reduktionsplan schneller als in bisherigen Studien die OCS-Dosis sicher reduziert werden kann bzw. OCS ganz abgesetzt werden können [3]. Zudem untermauern neue Real-World-Daten die Wirksamkeit und Verträglichkeit von Benralizumab im klinischen Alltag [4]. Dies stimmt auch mit persönlichen Erfahrungen aus der Praxis überein, wie ExpertInnen im Rahmen einer Presseveranstaltung berichteten. Die offene, multizentrische Extensionsstudie MELTEMI untersuchte über 130 Wochen die Sicherheit und Verträglichkeit der Langzeitanwendung von Benralizumab bei 446 PatientInnen mit schwerem eosinophilem Asthma [2]. Primärer Endpunkt war die langfristige Sicherheit, die anhand der Häufigkeiten von unerwünschten Ereignissen und schwerwiegenden unerwünschten Ereignissen gemessen wurde. Die vorliegenden Daten zeigen für Benralizumab ein konsistentes Sicherheitsprofil über eine Dauer von bis zu 5 Jahren [2].","PeriodicalId":17887,"journal":{"name":"Kompass Autoimmun","volume":"83 1","pages":"190 - 194"},"PeriodicalIF":0.0,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73912722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0